China-based Luye Pharma Group (HKG: 2186) has announced the initiation of commercialization of its in-house developed Erzofri (paliperidone palmitate extended-release injectable suspension) in the United States, with the first batch of products already shipped. This marks a significant milestone in the company’s global expansion strategy.
Erzofri: Long-Acting Injection for Schizophrenia
Erzofri is a long-acting injection designed to be administered once monthly. It contains paliperidone palmitate, a medication used for the treatment of schizophrenia and schizophrenic affective disorder. The drug was approved in the US in July of last year and is scheduled for prescription starting in April 2025.
Market Outlook and Strategic Implications
The commercialization of Erzofri in the US market underscores Luye Pharma’s commitment to providing innovative treatments for patients with schizophrenia. The once-monthly dosing regimen offers a convenient and effective option for managing these conditions, potentially improving patient adherence and outcomes. This launch is expected to enhance Luye Pharma’s presence in the global pharmaceutical market and contribute to its long-term growth strategy.-Fineline Info & Tech
Leave a Reply